Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer Q&A: Improving detection and reducing overtreatment

2.

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

3.

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

4.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

5.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot